Pallas Capital Advisors LLC Buys Shares of 9,853 Natera, Inc. $NTRA

Key Points

• Pallas Capital Advisors bought 9,853 Natera shares worth approximately $2.7 million in the second quarter. Institutional investors now own 99.90% of the company.
• Natera reported stronger-than-expected quarterly results, with revenue rising 37.7% year over year to $752.75 million and adjusted EPS of negative $0.47, beating estimates by $0.02.
• Analysts remain broadly bullish, with a “Moderate Buy” consensus rating and an average price target of $319.38. Natera shares opened at $314.18, near their 52-week high of $326.03.

Pallas Capital Advisors LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 9,853 shares of the medical research company's stock, valued at approximately $2,675,000.

A number of other large investors have also added to or reduced their stakes in NTRA. Deutsche Bank AG acquired a new position in Natera in the 2nd quarter valued at approximately $86,874,000. Perigon Wealth Management LLC bought a new stake in shares of Natera in the second quarter worth $622,000. Trust Co. of Vermont acquired a new stake in Natera in the second quarter valued at $26,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Natera during the 2nd quarter worth $50,424,000. Finally, OneDigital Investment Advisors LLC acquired a new position in Natera during the 2nd quarter worth about $460,000. Institutional investors own 99.90% of the company's stock.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 3,410 shares of Natera stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the sale, the insider owned 129,019 shares of the company's stock, valued at approximately $34,264,866.02. This trade represents a 2.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 41,124 shares of the business's stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the sale, the chief executive officer owned 108,743 shares in the company, valued at $24,035,465.29. This represents a 27.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 181,045 shares of company stock worth $41,330,968 in the last three months. Corporate insiders own 5.05% of the company's stock.

Natera Price Performance

NASDAQ NTRA opened at $314.18 on Tuesday. Natera, Inc. has a 1 year low of $156.71 and a 1 year high of $326.03. The firm has a market cap of $45.29 billion, a price-to-earnings ratio of -231.01 and a beta of 1.51. The company has a fifty day moving average price of $265.78 and a 200-day moving average price of $226.82.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same quarter in the previous year, the firm posted ($0.74) earnings per share. The company's revenue for the quarter was up 37.7% on a year-over-year basis. On average, research analysts anticipate that Natera, Inc. will post -1.11 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Sanford C. Bernstein began coverage on Natera in a research report on Friday, June 26th. They set an "outperform" rating and a $310.00 price objective for the company. Guggenheim raised their price target on shares of Natera from $290.00 to $360.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Wolfe Research initiated coverage on shares of Natera in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $260.00 price objective on the stock. Evercore restated an "outperform" rating and issued a $300.00 target price on shares of Natera in a report on Monday, July 6th. Finally, Royal Bank Of Canada increased their price target on Natera from $275.00 to $350.00 and gave the stock an "outperform" rating in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $319.38.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source